Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has scheduled its Q2 2020 financial results and conference call for August 7, 2020. The press release will be issued at 7:30 a.m. ET, followed by the conference call/webcast at 8:45 a.m. ET. Live access to the call can be found on Arbutus' website, with an archived version available afterward. Arbutus focuses on developing a cure for chronic hepatitis B virus infections and treatments for coronaviruses, including COVID-19. For more details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced positive results from its Phase 1a/1b clinical trial of AB-729, aimed at treating chronic hepatitis B virus (HBV) infection. The study showed a mean 0.99 log10 IU/mL reduction in HBsAg at week 12 with normal liver enzyme levels. The company is now advancing to multi-dose cohorts, dosing 60 mg of AB-729, and plans to release further data in late 2020. Interim findings suggest AB-729 is both effective and well-tolerated, supporting the goal of a combined therapy for chronic HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the UBS Virtual Global Healthcare Conference on May 19, 2020, at 11:40 AM ET. Interested parties can access the live webcast through the company's website. An archived replay will be available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B virus (HBV) infection with multiple drug candidates.